Breast tissue composition and immunophenotype and its relationship with mammographic density in women at high risk of breast cancer

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Pang, Jia Min B ^a,b   Byrne, David J ^a   Takano, Elena A ^a   Jene, Nicholas ^a   Petelin, Lara ^a   McKinley, Joanne ^a   Poliness, Catherine ^a   Saunders, Christobel ^c,d   Taylor, Donna ^c,d   Mitchell, Gillian ^a,b   Fox, Stephen B ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BREAST; BREAST BIOPSY; BREAST CANCER; BREAST DENSITY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOPHENOTYPING; MASTECTOMY; POSTMENOPAUSE; PROTEIN EXPRESSION; STROMA; ABNORMALITIES; ADIPOCYTE; BREAST NEOPLASMS; IMMUNOLOGY; MAMMARY GLAND; PATHOLOGY; PROCEDURES; RISK FACTOR; STROMA CELL;

ADIPOCYTES; BIOMARKERS; BREAST DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOPHENOTYPING; MAMMARY GLANDS, HUMAN; RISK FACTORS; STROMAL CELLS;

EID: 84938252816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128861     Document Type: Article

References (34)

1. Ginsburg OM, Martin LJ, Boyd NF (2008) Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 99: 1369-1374. doi: 10.1038/sj.bjc.6604635 PMID: 18781174
2. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, et al. (2009) The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomarkers Prev 18: 102-112. doi: 10.1158/1055-9965.EPI-07-2857 PMID: 19124487
3. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, et al. (2002) Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347: 886-894. PMID: 12239257
4. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103: 744-752. doi: 10.1093/jnci/djr079 PMID: 21483019
5. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, et al. (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14: 343-349. PMID: 15734956
6. Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, et al. (2012) Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat 131: 267-275. doi: 10.1007/s10549-011-1727-4 PMID: 21877142
7. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH (2003) Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 5: R129-135. PMID: 12927043
8. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, et al. (2011) Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 125: 243-252. doi: 10.1007/s10549-010-0944-6 PMID: 20526739
9. Lin SJ, Cawson J, Hill P, Haviv I, Jenkins M, Hopper JL, et al. (2011) Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. Breast Cancer Res Treat 128: 505-516. doi: 10.1007/s10549-011-1346-0 PMID: 21258862
10. National Breast and Ovarian Cancer Centre (2010). Advice about familial aspects of breast cancer and epithelial ovarian cancer- a guide for health professionals.
11. Wolfe JN (1976) Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37: 2486-2492. PMID: 1260729
12. Yan M, Rayoo M, Takano EA, Fox SB (2011) Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment 126: 395-405. doi: 10.1007/s10549-010-0941-9 PMID: 20490651
13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013. doi: 10.1200/JCO.2013.50.9984 PMID: 24101045
14. Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS, et al. (2008) Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 15: 67-73. PMID: 17558338
15. Hawes D, Downey S, Pearce CL, Bartow S, Wan P, Pike MC, et al. (2006) Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 8: R24. PMID: 16646977
16. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, et al. (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119: 305-314. doi: 10.1007/s10549-009-0350-0 PMID: 19241157
17. Kuhl H, Schneider HP (2013) Progesterone - promoter or inhibitor of breast cancer. Climacteric 16 Suppl 1: 54-68. doi: 10.3109/13697137.2013.768806 PMID: 23336704
18. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Söderqvist G, et al. (2002) Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186: 717-722. PMID: 11967497
19. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95: 30-37. PMID: 12509398
20. Vachon CM, Sellers TA, Vierkant RA, Wu FF, Brandt KR (2002) Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev 11: 1382-1388. PMID: 12433715
21. Dowsett M, Folkerd E (2015) Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Res Treat 149: 1-4. doi: 10.1007/s10549-014-3211-4 PMID: 25414027
22. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, van Noorden S, et al. (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98: 15197-15202. PMID: 11734621
23. Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55: 371-374. PMID: 11986344
24. Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, O'Hare MJ, et al. (2004) The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol 33: 35-50. PMID: 15291741
25. Boyd M, Hildebrandt RH, Bartow SA (1996) Expression of the estrogen receptor gene in developing and adult human breast. Breast Cancer Res Treat 37: 243-251. PMID: 8825136
26. Keeling JW, Ozer E, King G, Walker F (2000) Oestrogen receptor alpha in female fetal, infant, and child mammary tissue. J Pathol 191: 449-451. PMID: 10918221
27. Koerner F, Oyama T, Kurosumi M, Maluf H (2001) Ovarian hormone receptors in human mammary stromal cells. J Steroid Biochem Mol Biol 78: 285-290. PMID: 11595509
28. Huang Z, Zhu W, Szekeres G, Xia H (2005) Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol 13: 91-95. PMID: 15722800
29. Bae YK, Gong G, Kang J, Lee A, Cho EY, Lee JS, et al. (2012) Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays. Am J Surg Pathol 36: 1817-1825. doi: 10.1097/PAS.0b013e318267b012 PMID: 23154769
30. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24: 5637-5644. PMID: 17116944
31. Ko KL, Shin IS, You JY, Jung SY, Ro J, Lee ES (2013) Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat 142: 559-567. PMID: 24233999
32. Kim J, Han W, Moon HG, Ahn S, Shin HC, You JM, et al. (2012) Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 14: R102. doi: 10.1186/bcr3221 PMID: 22770227
33. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, et al. (2015) Prognostic Significance of Mammographic Density Change after Initiation of Tamoxifen for ER-Positive Breast Cancer. J Natl Cancer Inst 107.
34. Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 31: 2249-2256. doi: 10.1200/JCO.2012.44.5015 PMID: 23610119